Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma

Renal cell carcinoma (RCC) is the most aggressive type of genitourinary cancer and is resistant to current therapies. Identifying drugs that enhance the efficacy of RCC standard-of-care drugs at sublethal concentrations is an alternative therapeutic strategy. Ribociclib is an orally available cyclin...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Dehong, Sun, Xiaosong, Zhang, Xuejun, Cao, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306082/
https://www.ncbi.nlm.nih.gov/pubmed/32626773
http://dx.doi.org/10.1155/2020/9525207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306082/
https://www.ncbi.nlm.nih.gov/pubmed/32626773
http://dx.doi.org/10.1155/2020/9525207

Ejemplares similares